Dose Escalation from Paliperidone Palmitate 100mg Monthly
The next step to increase from paliperidone palmitate 100mg (156mg palmitate salt) every 4 weeks is to escalate to 117mg (paliperidone equivalent), which corresponds to 156mg of the palmitate salt formulation, administered monthly in either the deltoid or gluteal muscle. 1
Available Dose Escalation Options
According to the FDA-approved dosing for INVEGA SUSTENNA, monthly maintenance doses can be adjusted within the available strengths based on tolerability and efficacy 1:
- Current dose: 100mg eq. (156mg palmitate salt)
- Next escalation step: 117mg eq. (156mg palmitate salt) - Note: This appears to be the recommended maintenance dose
- Maximum dose: 156mg eq. (234mg palmitate salt) 1
The available monthly maintenance strengths are 39mg, 78mg, 117mg, 156mg, and 234mg (expressed as paliperidone equivalents) 1.
Administration Considerations
Site selection matters for the maintenance phase:
- Deltoid injection: Use 1-inch 23-gauge needle if patient weighs <90kg; use 1.5-inch 22-gauge needle if ≥90kg 1
- Gluteal injection: Use 1.5-inch 22-gauge needle regardless of weight 1
Research demonstrates that deltoid injections produce approximately 20-30% higher paliperidone exposure (AUC and Cmax) compared to gluteal injections, though both sites are acceptable for maintenance dosing 2.
Timing Flexibility
Monthly maintenance doses can be administered with a ±7 day window without clinically significant impact on plasma concentrations 1, 3, 4. This flexibility allows for practical scheduling while maintaining therapeutic drug levels.
Special Population Adjustments
For patients with mild renal impairment (CrCl 50-80 mL/min):
- The maximum monthly dose is capped at 156mg eq. (234mg palmitate salt) 1
- Dose adjustments should be made more cautiously in this population 1
INVEGA SUSTENNA is not recommended in patients with moderate or severe renal impairment (CrCl <50 mL/min) 1.
Clinical Monitoring
When escalating doses, assess for:
- Efficacy response: Improvement in positive and negative symptoms typically becomes evident within 8 days of appropriate dosing 5
- Tolerability: Monitor for extrapyramidal symptoms (EPS), which should be minimized to encourage adherence 6
- Injection site reactions: More common with deltoid administration 2
The dose should be increased only at widely spaced intervals (typically 14-21 days after initial titration) if response has been inadequate, and only within the limits of sedation and emergence of extrapyramidal side-effects 6.